Viking Global Investors’ fund specializing in private investments is off to another strong start this year. Viking Global Opportunities Drawdown was up 14.7 percent gross and 11.6 percent net in the ...
Paris (France) (AFP) – Les auditeurs de Radio France vont devoir changer certaines habitudes à la fin de l'été: France Musique ne sera plus diffusée qu'en numérique à certains endroits, dans un ...
Le groupe public entame une transition technologique majeure en réduisant la diffusion hertzienne de France Musique au profit du DAB + pour réaliser des économies Les auditeurs de Radio France vont ...
MusiquePlus a lancé une petite révolution dans le milieu télévisuel québécois. Une autre révolution, plus grande encore et à laquelle les patrons de la chaîne n’avaient pas de réponse, a provoqué sa ...
Viking will expand its river cruises across India in the coming years, adding several new departure dates through 2029 all before the company's first ship even set sails there. “Since announcing our ...
Get Travel Insider with Simon Calder. A newsletter packed with tips, deals, inspiration, and the latest travel news Get the Travel Insider newsletter with Simon Calder Viking Cruises has floated out ...
I last updated on Viking Therapeutics, Inc. (VKTX) in October last year, covering the company's Q3 earnings and business updates, and issued stock with a Buy rating - my sixth straight Buy call, in ...
LOS ANGELES--(BUSINESS WIRE)--Viking® (www.viking.com) (NYSE: VIK) today announced that the Viking Libra®, the world’s first hydrogen-powered cruise ship capable of operating with zero emissions, was ...
An independent researcher believes he’s discovered a legendary ruler’s burial site — a find that could be the first monumental Viking ship burial identified in England. Steve Dickinson, a British ...
Viking Holdings Ltd reported strong Q4 results. The company's fleet investments continue to drive growth, and improving operational metrics raise margins. VIK has a strong outlook ahead. The company ...
Novo Nordisk’s weight-loss drug CagriSema failed to meet a critical goal in late-stage clinical trials. This shortcoming bodes well for pharmaceutical companies working on similar obesity treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results